Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 18, 1997

View Archived Issues

New ECE inhibitors patented by Roussel Uclaf

Searle reports inhibitors of iNOS

New MMP inhibitors from Pharmacia & Upjohn

SUNY discloses new taxoids

Prodrugs of thrombin inhibitors prepared at BMS

Warner-Lambert describes novel anticonvulsants related to gabapentin

Potential of rhM-CIF in rheumatoid arthritis suggested by animal studies

Pharmacokinetic profile of Taisho's ACAT inhibitor

New cardiotonic candidate studied, rejected at Fujisawa

Dainippon develops sustained-release morphine preparation

Pharmacokinetic profile of ciclosporin derivative IMM-125

COX-2 antisense therapy for rheumatoid arthritis

Improvement in early and established arthritis with antiangiogenic therapy

Data presented on Shionogi's S-2150

Safety, immunogenicity and efficacy of anti-TNF antibody in RA patients

FDA clears new Tilade formulation

TpP, FiF introduced to medical community at major trade show

SomatoKine shows potential for the treatment of osteoporosis

Second report of clinical efficacy for rotavirus vaccine

LXR's patented drug screening technology yields two novel apoptosis-suppressing agents

Second-generation, highly selective COX-2 inhibitors developed at Merck

Bristol-Myers Squibb: Q3 1997 highlights

Merck & Co. isolates novel antifungal agent with potent, broad-spectrum activity

Evidence that Theratope elicits an antitumor cellular immune response presented

International phase III trial of Maxamine in malignant melanoma

Sano: Q3 and nine-month highlights

FDA clears first inhaled corticosteroid for young children with asthma

Schering-Plough obtains rights to Vasomax

U.S. patent coverage for Verex's controlled-release AZT product

MiKasome enters phase II for UTI

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...